Drugs / Mycobacterium obuense
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01539824 | May 2012 → Mar 2014 | colorectal cancer | Immodulon Therapeutics Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mycobacterium obuense | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01539824 ↗ |
| Known as | IMM-101 | “IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.” NCT01539824 ↗ |